Elekta AB (publ) (EKTAY) Stock Competitors & Peer Comparison
See (EKTAY) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EKTAY | $5.63 | +0.20% | 2.2B | -38.37 | -$0.15 | +4.60% |
| SRTOY | $20.45 | +0.54% | 199.2B | 64.00 | $0.32 | +0.40% |
| ESLOY | $98.36 | -2.07% | 91.1B | 34.20 | $2.90 | +2.37% |
| ESLOF | $205.10 | +0.83% | 90.8B | 33.93 | $5.78 | +2.40% |
| SOAGY | $56.42 | -0.34% | 82.8B | 102.99 | $0.55 | +0.30% |
| HOCPY | $171.90 | +3.65% | 55.7B | 35.71 | $4.66 | +1.03% |
| HOCPF | $160.69 | -3.30% | 53.8B | 34.48 | $4.66 | +1.19% |
| MECNY | $88.63 | +0.00% | 26.9B | N/A | N/A | N/A |
| TRUMY | $14.18 | -3.08% | 20.8B | 24.35 | $0.58 | +1.22% |
| TRUMF | $13.60 | -10.05% | 20.1B | 23.45 | $0.58 | +1.44% |
Stock Comparison
EKTAY vs SRTOY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SRTOY has a market cap of 199.2B. Regarding current trading prices, EKTAY is priced at $5.63, while SRTOY trades at $20.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SRTOY's P/E ratio is 64.00. In terms of profitability, EKTAY's ROE is -0.06%, compared to SRTOY's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SRTOY's competition here
EKTAY vs ESLOY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ESLOY has a market cap of 91.1B. Regarding current trading prices, EKTAY is priced at $5.63, while ESLOY trades at $98.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas ESLOY's P/E ratio is 34.20. In terms of profitability, EKTAY's ROE is -0.06%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to ESLOY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ESLOY's competition here
EKTAY vs ESLOF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ESLOF has a market cap of 90.8B. Regarding current trading prices, EKTAY is priced at $5.63, while ESLOF trades at $205.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas ESLOF's P/E ratio is 33.93. In terms of profitability, EKTAY's ROE is -0.06%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to ESLOF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ESLOF's competition here
EKTAY vs SOAGY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SOAGY has a market cap of 82.8B. Regarding current trading prices, EKTAY is priced at $5.63, while SOAGY trades at $56.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SOAGY's P/E ratio is 102.99. In terms of profitability, EKTAY's ROE is -0.06%, compared to SOAGY's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to SOAGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SOAGY's competition here
EKTAY vs HOCPY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, HOCPY has a market cap of 55.7B. Regarding current trading prices, EKTAY is priced at $5.63, while HOCPY trades at $171.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas HOCPY's P/E ratio is 35.71. In terms of profitability, EKTAY's ROE is -0.06%, compared to HOCPY's ROE of +0.25%. Regarding short-term risk, EKTAY is less volatile compared to HOCPY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check HOCPY's competition here
EKTAY vs HOCPF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, HOCPF has a market cap of 53.8B. Regarding current trading prices, EKTAY is priced at $5.63, while HOCPF trades at $160.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas HOCPF's P/E ratio is 34.48. In terms of profitability, EKTAY's ROE is -0.06%, compared to HOCPF's ROE of +0.25%. Regarding short-term risk, EKTAY is more volatile compared to HOCPF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check HOCPF's competition here
EKTAY vs MECNY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MECNY has a market cap of 26.9B. Regarding current trading prices, EKTAY is priced at $5.63, while MECNY trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas MECNY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, EKTAY is more volatile compared to MECNY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MECNY's competition here
EKTAY vs TRUMY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TRUMY has a market cap of 20.8B. Regarding current trading prices, EKTAY is priced at $5.63, while TRUMY trades at $14.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas TRUMY's P/E ratio is 24.35. In terms of profitability, EKTAY's ROE is -0.06%, compared to TRUMY's ROE of +0.09%. Regarding short-term risk, EKTAY is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TRUMY's competition here
EKTAY vs TRUMF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TRUMF has a market cap of 20.1B. Regarding current trading prices, EKTAY is priced at $5.63, while TRUMF trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas TRUMF's P/E ratio is 23.45. In terms of profitability, EKTAY's ROE is -0.06%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, EKTAY is more volatile compared to TRUMF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check TRUMF's competition here
EKTAY vs SDMHF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SDMHF has a market cap of 19.9B. Regarding current trading prices, EKTAY is priced at $5.63, while SDMHF trades at $204.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SDMHF's P/E ratio is 63.86. In terms of profitability, EKTAY's ROE is -0.06%, compared to SDMHF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to SDMHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SDMHF's competition here
EKTAY vs SAUHF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SAUHF has a market cap of 19.7B. Regarding current trading prices, EKTAY is priced at $5.63, while SAUHF trades at $123.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SAUHF's P/E ratio is 43.65. In terms of profitability, EKTAY's ROE is -0.06%, compared to SAUHF's ROE of +0.17%. Regarding short-term risk, EKTAY is more volatile compared to SAUHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SAUHF's competition here
EKTAY vs SUVPF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SUVPF has a market cap of 19.1B. Regarding current trading prices, EKTAY is priced at $5.63, while SUVPF trades at $276.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SUVPF's P/E ratio is 100.93. In terms of profitability, EKTAY's ROE is -0.06%, compared to SUVPF's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to SUVPF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SUVPF's competition here
EKTAY vs SAUHY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SAUHY has a market cap of 19B. Regarding current trading prices, EKTAY is priced at $5.63, while SAUHY trades at $11.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SAUHY's P/E ratio is 42.54. In terms of profitability, EKTAY's ROE is -0.06%, compared to SAUHY's ROE of +0.17%. Regarding short-term risk, EKTAY is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SAUHY's competition here
EKTAY vs SSSGY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SSSGY has a market cap of 15.2B. Regarding current trading prices, EKTAY is priced at $5.63, while SSSGY trades at $43.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SSSGY's P/E ratio is 79.85. In terms of profitability, EKTAY's ROE is -0.06%, compared to SSSGY's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to SSSGY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SSSGY's competition here
EKTAY vs SARTF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SARTF has a market cap of 15B. Regarding current trading prices, EKTAY is priced at $5.63, while SARTF trades at $217.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SARTF's P/E ratio is 80.02. In terms of profitability, EKTAY's ROE is -0.06%, compared to SARTF's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to SARTF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SARTF's competition here
EKTAY vs FSPKF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, FSPKF has a market cap of 12.1B. Regarding current trading prices, EKTAY is priced at $5.63, while FSPKF trades at $20.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas FSPKF's P/E ratio is 46.70. In terms of profitability, EKTAY's ROE is -0.06%, compared to FSPKF's ROE of +0.23%. Regarding short-term risk, EKTAY is more volatile compared to FSPKF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check FSPKF's competition here
EKTAY vs AHICF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, AHICF has a market cap of 5.7B. Regarding current trading prices, EKTAY is priced at $5.63, while AHICF trades at $21.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas AHICF's P/E ratio is 50.96. In terms of profitability, EKTAY's ROE is -0.06%, compared to AHICF's ROE of +0.20%. Regarding short-term risk, EKTAY is less volatile compared to AHICF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check AHICF's competition here
EKTAY vs SSMXY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SSMXY has a market cap of 5.6B. Regarding current trading prices, EKTAY is priced at $5.63, while SSMXY trades at $9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SSMXY's P/E ratio is 24.94. In terms of profitability, EKTAY's ROE is -0.06%, compared to SSMXY's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to SSMXY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SSMXY's competition here
EKTAY vs SSMXF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SSMXF has a market cap of 5.5B. Regarding current trading prices, EKTAY is priced at $5.63, while SSMXF trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SSMXF's P/E ratio is 24.58. In terms of profitability, EKTAY's ROE is -0.06%, compared to SSMXF's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to SSMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SSMXF's competition here
EKTAY vs CNVVF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CNVVF has a market cap of 5.3B. Regarding current trading prices, EKTAY is priced at $5.63, while CNVVF trades at $2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas CNVVF's P/E ratio is 30.00. In terms of profitability, EKTAY's ROE is -0.06%, compared to CNVVF's ROE of +0.11%. Regarding short-term risk, EKTAY is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CNVVF's competition here
EKTAY vs CNVVY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CNVVY has a market cap of 5.2B. Regarding current trading prices, EKTAY is priced at $5.63, while CNVVY trades at $10.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas CNVVY's P/E ratio is 31.21. In terms of profitability, EKTAY's ROE is -0.06%, compared to CNVVY's ROE of +0.10%. Regarding short-term risk, EKTAY is more volatile compared to CNVVY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CNVVY's competition here
EKTAY vs FLMNF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, FLMNF has a market cap of 4.3B. Regarding current trading prices, EKTAY is priced at $5.63, while FLMNF trades at $50.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas FLMNF's P/E ratio is 17.87. In terms of profitability, EKTAY's ROE is -0.06%, compared to FLMNF's ROE of +0.22%. Regarding short-term risk, EKTAY is less volatile compared to FLMNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check FLMNF's competition here
EKTAY vs FLMNY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, FLMNY has a market cap of 4.2B. Regarding current trading prices, EKTAY is priced at $5.63, while FLMNY trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas FLMNY's P/E ratio is 17.43. In terms of profitability, EKTAY's ROE is -0.06%, compared to FLMNY's ROE of +0.21%. Regarding short-term risk, EKTAY is less volatile compared to FLMNY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check FLMNY's competition here
EKTAY vs ANSLF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ANSLF has a market cap of 3.2B. Regarding current trading prices, EKTAY is priced at $5.63, while ANSLF trades at $19.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas ANSLF's P/E ratio is 32.49. In terms of profitability, EKTAY's ROE is -0.06%, compared to ANSLF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to ANSLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ANSLF's competition here
EKTAY vs ANSLY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ANSLY has a market cap of 2.7B. Regarding current trading prices, EKTAY is priced at $5.63, while ANSLY trades at $74.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas ANSLY's P/E ratio is 19.99. In terms of profitability, EKTAY's ROE is -0.06%, compared to ANSLY's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to ANSLY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ANSLY's competition here
EKTAY vs CZMWY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CZMWY has a market cap of 2.6B. Regarding current trading prices, EKTAY is priced at $5.63, while CZMWY trades at $30.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas CZMWY's P/E ratio is 16.18. In terms of profitability, EKTAY's ROE is -0.06%, compared to CZMWY's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to CZMWY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CZMWY's competition here
EKTAY vs CZMWF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CZMWF has a market cap of 2.6B. Regarding current trading prices, EKTAY is priced at $5.63, while CZMWF trades at $29.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas CZMWF's P/E ratio is 16.09. In terms of profitability, EKTAY's ROE is -0.06%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to CZMWF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CZMWF's competition here
EKTAY vs EKTAF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, EKTAF has a market cap of 2.4B. Regarding current trading prices, EKTAY is priced at $5.63, while EKTAF trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas EKTAF's P/E ratio is -43.33. In terms of profitability, EKTAY's ROE is -0.06%, compared to EKTAF's ROE of -0.06%. Regarding short-term risk, EKTAY is more volatile compared to EKTAF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check EKTAF's competition here
EKTAY vs SHWGY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SHWGY has a market cap of 2B. Regarding current trading prices, EKTAY is priced at $5.63, while SHWGY trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SHWGY's P/E ratio is 8.29. In terms of profitability, EKTAY's ROE is -0.06%, compared to SHWGY's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to SHWGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SHWGY's competition here
EKTAY vs SHWGF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SHWGF has a market cap of 2B. Regarding current trading prices, EKTAY is priced at $5.63, while SHWGF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SHWGF's P/E ratio is 8.80. In terms of profitability, EKTAY's ROE is -0.06%, compared to SHWGF's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to SHWGF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SHWGF's competition here
EKTAY vs ADDLF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ADDLF has a market cap of 1.8B. Regarding current trading prices, EKTAY is priced at $5.63, while ADDLF trades at $15.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas ADDLF's P/E ratio is 31.50. In terms of profitability, EKTAY's ROE is -0.06%, compared to ADDLF's ROE of +0.11%. Regarding short-term risk, EKTAY is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ADDLF's competition here
EKTAY vs NPRRF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, EKTAY is priced at $5.63, while NPRRF trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas NPRRF's P/E ratio is 21.65. In terms of profitability, EKTAY's ROE is -0.06%, compared to NPRRF's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to NPRRF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check NPRRF's competition here
EKTAY vs TGLVY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TGLVY has a market cap of 1.4B. Regarding current trading prices, EKTAY is priced at $5.63, while TGLVY trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas TGLVY's P/E ratio is 35.98. In terms of profitability, EKTAY's ROE is -0.06%, compared to TGLVY's ROE of +0.03%. Regarding short-term risk, EKTAY is less volatile compared to TGLVY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TGLVY's competition here
EKTAY vs BITGF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, EKTAY is priced at $5.63, while BITGF trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas BITGF's P/E ratio is 45.50. In terms of profitability, EKTAY's ROE is -0.06%, compared to BITGF's ROE of +0.04%. Regarding short-term risk, EKTAY is less volatile compared to BITGF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check BITGF's competition here
EKTAY vs PBHDF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, PBHDF has a market cap of 1.2B. Regarding current trading prices, EKTAY is priced at $5.63, while PBHDF trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, EKTAY's ROE is -0.06%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to PBHDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check PBHDF's competition here
EKTAY vs SAFLY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SAFLY has a market cap of 1.1B. Regarding current trading prices, EKTAY is priced at $5.63, while SAFLY trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SAFLY's P/E ratio is 13.93. In terms of profitability, EKTAY's ROE is -0.06%, compared to SAFLY's ROE of +0.12%. Regarding short-term risk, EKTAY is less volatile compared to SAFLY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SAFLY's competition here
EKTAY vs GRRMF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, GRRMF has a market cap of 1.1B. Regarding current trading prices, EKTAY is priced at $5.63, while GRRMF trades at $32.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas GRRMF's P/E ratio is 40.63. In terms of profitability, EKTAY's ROE is -0.06%, compared to GRRMF's ROE of +0.02%. Regarding short-term risk, EKTAY is more volatile compared to GRRMF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check GRRMF's competition here
EKTAY vs JNDOF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, JNDOF has a market cap of 1.1B. Regarding current trading prices, EKTAY is priced at $5.63, while JNDOF trades at $47.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas JNDOF's P/E ratio is 98.38. In terms of profitability, EKTAY's ROE is -0.06%, compared to JNDOF's ROE of +0.23%. Regarding short-term risk, EKTAY is more volatile compared to JNDOF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check JNDOF's competition here
EKTAY vs TDVXF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TDVXF has a market cap of 920.6M. Regarding current trading prices, EKTAY is priced at $5.63, while TDVXF trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas TDVXF's P/E ratio is 48.46. In terms of profitability, EKTAY's ROE is -0.06%, compared to TDVXF's ROE of +0.32%. Regarding short-term risk, EKTAY is more volatile compared to TDVXF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check TDVXF's competition here
EKTAY vs SAFLF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SAFLF has a market cap of 906.6M. Regarding current trading prices, EKTAY is priced at $5.63, while SAFLF trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SAFLF's P/E ratio is 16.50. In terms of profitability, EKTAY's ROE is -0.06%, compared to SAFLF's ROE of +0.12%. Regarding short-term risk, EKTAY is more volatile compared to SAFLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SAFLF's competition here
EKTAY vs KSRBF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, KSRBF has a market cap of 839.6M. Regarding current trading prices, EKTAY is priced at $5.63, while KSRBF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas KSRBF's P/E ratio is 33.29. In terms of profitability, EKTAY's ROE is -0.06%, compared to KSRBF's ROE of +0.04%. Regarding short-term risk, EKTAY is more volatile compared to KSRBF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check KSRBF's competition here
EKTAY vs HGYMF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, HGYMF has a market cap of 754.4M. Regarding current trading prices, EKTAY is priced at $5.63, while HGYMF trades at $34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas HGYMF's P/E ratio is 184.16. In terms of profitability, EKTAY's ROE is -0.06%, compared to HGYMF's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to HGYMF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check HGYMF's competition here
EKTAY vs NNCSF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, NNCSF has a market cap of 747M. Regarding current trading prices, EKTAY is priced at $5.63, while NNCSF trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas NNCSF's P/E ratio is 50.00. In terms of profitability, EKTAY's ROE is -0.06%, compared to NNCSF's ROE of +0.10%. Regarding short-term risk, EKTAY is more volatile compared to NNCSF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check NNCSF's competition here
EKTAY vs SPMXF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, EKTAY is priced at $5.63, while SPMXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, EKTAY's ROE is -0.06%, compared to SPMXF's ROE of -0.08%. Regarding short-term risk, EKTAY is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SPMXF's competition here
EKTAY vs CLHLF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, EKTAY is priced at $5.63, while CLHLF trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, EKTAY's ROE is -0.06%, compared to CLHLF's ROE of +0.16%. Regarding short-term risk, EKTAY is more volatile compared to CLHLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CLHLF's competition here
EKTAY vs TSNLF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TSNLF has a market cap of 265.4M. Regarding current trading prices, EKTAY is priced at $5.63, while TSNLF trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas TSNLF's P/E ratio is 25.14. In terms of profitability, EKTAY's ROE is -0.06%, compared to TSNLF's ROE of +0.24%. Regarding short-term risk, EKTAY is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TSNLF's competition here
EKTAY vs OPSSF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, EKTAY is priced at $5.63, while OPSSF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, EKTAY's ROE is -0.06%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, EKTAY is less volatile compared to OPSSF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check OPSSF's competition here
EKTAY vs EEOIF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, EKTAY is priced at $5.63, while EEOIF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, EKTAY's ROE is -0.06%, compared to EEOIF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to EEOIF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check EEOIF's competition here
EKTAY vs OTCFF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, OTCFF has a market cap of 23.4M. Regarding current trading prices, EKTAY is priced at $5.63, while OTCFF trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas OTCFF's P/E ratio is -13.52. In terms of profitability, EKTAY's ROE is -0.06%, compared to OTCFF's ROE of +1.88%. Regarding short-term risk, EKTAY is more volatile compared to OTCFF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OTCFF's competition here
EKTAY vs UEEC Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, UEEC has a market cap of 14.6M. Regarding current trading prices, EKTAY is priced at $5.63, while UEEC trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas UEEC's P/E ratio is -5.60. In terms of profitability, EKTAY's ROE is -0.06%, compared to UEEC's ROE of +0.40%. Regarding short-term risk, EKTAY is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check UEEC's competition here
EKTAY vs BLMHF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, EKTAY is priced at $5.63, while BLMHF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, EKTAY's ROE is -0.06%, compared to BLMHF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to BLMHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BLMHF's competition here
EKTAY vs PXMVF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, EKTAY is priced at $5.63, while PXMVF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, EKTAY's ROE is -0.06%, compared to PXMVF's ROE of -6.46%. Regarding short-term risk, EKTAY is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check PXMVF's competition here
EKTAY vs CBSC Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CBSC has a market cap of 4.5M. Regarding current trading prices, EKTAY is priced at $5.63, while CBSC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas CBSC's P/E ratio is -4.00. In terms of profitability, EKTAY's ROE is -0.06%, compared to CBSC's ROE of +0.58%. Regarding short-term risk, EKTAY is less volatile compared to CBSC. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CBSC's competition here
EKTAY vs MCDA Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, EKTAY is priced at $5.63, while MCDA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas MCDA's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to MCDA's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to MCDA. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MCDA's competition here
EKTAY vs RSCF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, RSCF has a market cap of 4.1M. Regarding current trading prices, EKTAY is priced at $5.63, while RSCF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas RSCF's P/E ratio is -4.75. In terms of profitability, EKTAY's ROE is -0.06%, compared to RSCF's ROE of +0.10%. Regarding short-term risk, EKTAY is less volatile compared to RSCF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check RSCF's competition here
EKTAY vs TUTH Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TUTH has a market cap of 3.6M. Regarding current trading prices, EKTAY is priced at $5.63, while TUTH trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas TUTH's P/E ratio is -1.42. In terms of profitability, EKTAY's ROE is -0.06%, compared to TUTH's ROE of +0.27%. Regarding short-term risk, EKTAY is less volatile compared to TUTH. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TUTH's competition here
EKTAY vs NSTGQ Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, EKTAY is priced at $5.63, while NSTGQ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check NSTGQ's competition here
EKTAY vs GVDI Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, GVDI has a market cap of 2.2M. Regarding current trading prices, EKTAY is priced at $5.63, while GVDI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas GVDI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to GVDI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check GVDI's competition here
EKTAY vs YBGJ Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, YBGJ has a market cap of 1M. Regarding current trading prices, EKTAY is priced at $5.63, while YBGJ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas YBGJ's P/E ratio is -0.84. In terms of profitability, EKTAY's ROE is -0.06%, compared to YBGJ's ROE of +0.37%. Regarding short-term risk, EKTAY is more volatile compared to YBGJ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check YBGJ's competition here
EKTAY vs OJSY Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, EKTAY is priced at $5.63, while OJSY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas OJSY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to OJSY's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to OJSY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OJSY's competition here
EKTAY vs PDMI Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, EKTAY is priced at $5.63, while PDMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas PDMI's P/E ratio is -0.01. In terms of profitability, EKTAY's ROE is -0.06%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, EKTAY is more volatile compared to PDMI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check PDMI's competition here
EKTAY vs WHSI Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, EKTAY is priced at $5.63, while WHSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas WHSI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, EKTAY is more volatile compared to WHSI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check WHSI's competition here
EKTAY vs BLFE Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, EKTAY is priced at $5.63, while BLFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas BLFE's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to BLFE's ROE of +3.67%. Regarding short-term risk, EKTAY is more volatile compared to BLFE. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BLFE's competition here
EKTAY vs ECIA Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ECIA has a market cap of 124.5K. Regarding current trading prices, EKTAY is priced at $5.63, while ECIA trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas ECIA's P/E ratio is -0.33. In terms of profitability, EKTAY's ROE is -0.06%, compared to ECIA's ROE of -0.22%. Regarding short-term risk, EKTAY is less volatile compared to ECIA. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ECIA's competition here
EKTAY vs QTXB Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, EKTAY is priced at $5.63, while QTXB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas QTXB's P/E ratio is -0.05. In terms of profitability, EKTAY's ROE is -0.06%, compared to QTXB's ROE of +0.19%. Regarding short-term risk, EKTAY is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check QTXB's competition here
EKTAY vs LANZ Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, LANZ has a market cap of 110.4K. Regarding current trading prices, EKTAY is priced at $5.63, while LANZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas LANZ's P/E ratio is 4.00. In terms of profitability, EKTAY's ROE is -0.06%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, EKTAY is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check LANZ's competition here
EKTAY vs CEOS Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CEOS has a market cap of 94.7K. Regarding current trading prices, EKTAY is priced at $5.63, while CEOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas CEOS's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to CEOS's ROE of +7.33%. Regarding short-term risk, EKTAY is less volatile compared to CEOS. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CEOS's competition here
EKTAY vs IMTH Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, IMTH has a market cap of 89.8K. Regarding current trading prices, EKTAY is priced at $5.63, while IMTH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas IMTH's P/E ratio is -0.03. In terms of profitability, EKTAY's ROE is -0.06%, compared to IMTH's ROE of -0.60%. Regarding short-term risk, EKTAY is more volatile compared to IMTH. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check IMTH's competition here
EKTAY vs GMVDF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, EKTAY is priced at $5.63, while GMVDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas GMVDF's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, EKTAY is more volatile compared to GMVDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check GMVDF's competition here
EKTAY vs REMI Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, REMI has a market cap of 14K. Regarding current trading prices, EKTAY is priced at $5.63, while REMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas REMI's P/E ratio is -0.07. In terms of profitability, EKTAY's ROE is -0.06%, compared to REMI's ROE of -0.11%. Regarding short-term risk, EKTAY is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check REMI's competition here
EKTAY vs SDCCQ Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SDCCQ has a market cap of 13.4K. Regarding current trading prices, EKTAY is priced at $5.63, while SDCCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, EKTAY is more volatile compared to SDCCQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SDCCQ's competition here
EKTAY vs MDIT Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MDIT has a market cap of 8.7K. Regarding current trading prices, EKTAY is priced at $5.63, while MDIT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas MDIT's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, EKTAY is more volatile compared to MDIT. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MDIT's competition here
EKTAY vs ASFX Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ASFX has a market cap of 5.3K. Regarding current trading prices, EKTAY is priced at $5.63, while ASFX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas ASFX's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to ASFX. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ASFX's competition here
EKTAY vs DGEN Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, EKTAY is priced at $5.63, while DGEN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas DGEN's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to DGEN. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check DGEN's competition here
EKTAY vs SVSO Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, EKTAY is priced at $5.63, while SVSO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SVSO's P/E ratio is -0.01. In terms of profitability, EKTAY's ROE is -0.06%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, EKTAY is more volatile compared to SVSO. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SVSO's competition here
EKTAY vs LFPI Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, LFPI has a market cap of 2.1K. Regarding current trading prices, EKTAY is priced at $5.63, while LFPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas LFPI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, EKTAY is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check LFPI's competition here
EKTAY vs SEYE Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, EKTAY is priced at $5.63, while SEYE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SEYE's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to SEYE's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to SEYE. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SEYE's competition here
EKTAY vs BGMD Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, EKTAY is priced at $5.63, while BGMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas BGMD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to BGMD's ROE of +7.47%. Regarding short-term risk, EKTAY is more volatile compared to BGMD. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BGMD's competition here
EKTAY vs ADLI Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, EKTAY is priced at $5.63, while ADLI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas ADLI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, EKTAY is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ADLI's competition here
EKTAY vs VSMD Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, VSMD has a market cap of 802. Regarding current trading prices, EKTAY is priced at $5.63, while VSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas VSMD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, EKTAY is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check VSMD's competition here
EKTAY vs TEVNF Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TEVNF has a market cap of 744. Regarding current trading prices, EKTAY is priced at $5.63, while TEVNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas TEVNF's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, EKTAY is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TEVNF's competition here
EKTAY vs INND Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, INND has a market cap of 573. Regarding current trading prices, EKTAY is priced at $5.63, while INND trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas INND's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to INND's ROE of -0.01%. Regarding short-term risk, EKTAY is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check INND's competition here
EKTAY vs HRAL Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, HRAL has a market cap of 396. Regarding current trading prices, EKTAY is priced at $5.63, while HRAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas HRAL's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to HRAL's ROE of +0.21%. Regarding short-term risk, EKTAY is more volatile compared to HRAL. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check HRAL's competition here
EKTAY vs MICRD Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MICRD has a market cap of 317. Regarding current trading prices, EKTAY is priced at $5.63, while MICRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas MICRD's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is -0.06%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, EKTAY is more volatile compared to MICRD. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MICRD's competition here
EKTAY vs RGBOQ Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, EKTAY is priced at $5.63, while RGBOQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is -0.06%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to RGBOQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check RGBOQ's competition here
EKTAY vs SECI Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SECI has a market cap of 31. Regarding current trading prices, EKTAY is priced at $5.63, while SECI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas SECI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to SECI's ROE of -0.00%. Regarding short-term risk, EKTAY is more volatile compared to SECI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SECI's competition here
EKTAY vs VTEQ Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, EKTAY is priced at $5.63, while VTEQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is -0.06%, compared to VTEQ's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to VTEQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check VTEQ's competition here
EKTAY vs MEDVD Comparison June 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MEDVD has a market cap of 0. Regarding current trading prices, EKTAY is priced at $5.63, while MEDVD trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -38.37, whereas MEDVD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.06%, compared to MEDVD's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to MEDVD. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MEDVD's competition here